You are here:
Myelodysplastic syndromes (MDS); transfusion-dependent and relapsed after or refractory to prior therapy.
No judgement
Clinical trials
Imetelstat
Oncology and Hematology
Leukemia
Janssenbiologic
Intravenous
Intravenous drip
Intermural (MSZ)
Fabrikant volledig: Geron Corp. / Janssen Biotech NV. A first-in-class telomerase inhibitor.
Centralised (EMA)
New medicine
2019
2020
No
Weesgeneesmiddel in de US niet in EU.
Bloedtransfusies, chemotherapie gevolgd door beenmergtransplantatie.
1 times every 4 weeks
7,5 mg/kg
NCT02598661
NKR
Aantal diagnoses myelodysplastisch syndroom in 2016: 810.
There is currently nothing known about the expected cost.
There is currently nothing known about the possible total cost.
There is currently nothing known about off label use.
Yes
Primary or secondary myelofibrosis.
SPS
There is currently no futher information available.
Understanding of expected market entry of innovative medicines